Integrated Nano-Technologies

    Founded in 2000 by an interdisciplinary team of scientists and engineers, INT has addressed not only the technological barriers of streamlining such complex and diverse processes into a portable platform, but has approached it with the input and support of its target customers, governmental agencies, and global foundations.
    Michael is the Chairman of the Board. He is also President and Chief Executive Officer of the Company. He has a PhD in molecular biology from Northwestern University and completed a post-doctoral fellowship in the Department of Microbiology at the University of Illinois Medical Center. After completing his JD at Cornell University, he practiced as a patent attorney at Nixon Peabody, LLP in Rochester. While at Nixon Peabody, he played a significant role in developing the licensing strategy for a major genetic sequencing enterprise, as well as patenting and licensing technologies for several other companies and universities.
    Ron joined the company in 2016 as the Chief Financial Officer. Prior to INT, Ron was the Vice President of Biosensors International Group, a $300 million international medical device company, where he also served as General Manager of the U.S. R&D center overseeing the development of novel devices for the treatment of peripheral artery disease. Previously, Ron co-founded Verdant Medical, a start-up focused on treatments for peripheral artery disease (acquired by Biosensors). Ron also served as General Counsel and Corporate Secretary of XTENT, Inc., a NASDAQ-listed medical device company. Ron began his career as a practicing corporate and securities attorney with Silicon Valley Law Group where he focused on financings and M&A transactions for technology startups. Ron holds a Juris Doctor degree and a Masters of Business Administration degree from the University of Maine. 
    Stay in the know on INT technology!
    Get started here!